<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="23743">Dihydrofolate</z:chebi> reductase (<z:chebi fb="0" ids="50314">FH2</z:chebi>-R) was studied cytochemically in the bone marrow erythroblasts of 20 <z:mpath ids='MPATH_458'>normal</z:mpath> controls and 46 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) classified according to FAB, prior to therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The reaction product was quantified for the same samples with a Vickers M86 microdensitometer </plain></SENT>
<SENT sid="2" pm="."><plain>The enzyme activity progressively decreased during the <z:mpath ids='MPATH_458'>normal</z:mpath> differentiation of the erythroid cells and persisted at high levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>The high level of <z:chebi fb="0" ids="50314">FH2</z:chebi>-R may be related to the <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of the cells, or to increased compensatory erythropoietic activity of <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo>, or to both </plain></SENT>
</text></document>